Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

BACKGROUNDNew therapies for metastatic non-small cell lung cancer (NSCLC) have improved survival in clinical trials. However, only a minority of patients receive systemic therapy. This article reports treatment patterns and outcomes for a population of Canadian patients with metastatic NSCLC (Ontario). METHODSPatients diagnosed with stage IV NSCLC from 2005 to 2009 were identified through multiple linked provincial databases. Patient demographics, systemic treatment, and survival were examined over time. RESULTSMetastatic NSCLC patients (n=8113) were identified. The median age was 68 years; 39% had adenocarcinoma, 14% had squamous carcinoma, and a higher than expected proportion (43%) had NSCLC not otherwise specified. Only 24% the patients received first-line chemotherapy; only 31% of these received second-line chemotherapy. More patients received systemic therapy over time (from 19% in 2005 to 26% in 2009, P<.0001). Patients who were less than 70 years old or had adenocarcinoma were more likely to receive systemic therapy (P<.0001 for both). The median survival, regardless of age, for those selected to receive first-line cisplatin-gemcitabine chemotherapy was longer than that for those receiving other nonpemetrexed platinum doublets at 11.6 months (P=.0002). Patients with nonsquamous histology who were treated with second-line pemetrexed had longer median survival than those treated with docetaxel (19.8 vs 14.1 months, P<.0001). CONCLUSIONSMost patients with metastatic NSCLC in the general population still do not receive systemic therapy. Those selected for first- and second-line systemic treatment, including older patients, have survival outcomes comparable to clinical trial results. Older patients and patients with squamous histology are less likely to receive chemotherapy. The low levels of treatment utilization in this study warrant further investigation. Cancer 2015;121:2562-2569. (c) 2015 American Cancer Society. Most patients with metastatic non-small cell lung cancer in the general population still do not receive systemic therapy.